The paper discussed the dual effects of dupilumab, an anti-IL4/IL13 monoclonal antibody, on patients with atopic dermatitis (AD) and alopecia areata (AA). While some patients experienced healing of AA during dupilumab treatment for AD, others developed AA as a side effect. The authors reported two cases illustrating these contrasting outcomes, highlighting the complex and unpredictable nature of dupilumab's impact on AA.
How diffuse unpatterned alopecia (DUPA) is not an invitation to self-diagnose oneself with aggressive AGA and that seeking a specialized dermatologist may help people experiencing hair loss. Treatment options discussed include topical clobetasol propionate, oral minoxidil, and discontinuing finasteride.
The user is experiencing diffuse thinning and inflammation despite using 2.5mg dutasteride daily, ciclopirox, and ketoconazole shampoos. They are considering treatments like hydroxychloroquine and JAK inhibitors due to suspected scarring alopecia and have faced challenges in obtaining a scalp biopsy.
The user has DUPA and suspects autoimmune activity as a cause. They have tried various treatments including finasteride, minoxidil, dutasteride, pyrilutamide, estrogel, hydrocortisone, and clobetasol, and are now seeking a long-term immunosuppressant.
The conversation discusses diffuse unpatterned alopecia (DUPA) and its possible causes, including sensitivity to DHT, not being androgenic alopecia, being diffuse alopeciaareata, or hormonal issues. Treatments mentioned include topical melatonin, Clobetasol Propionate for alopeciaareata, and the lack of results from using finasteride, dutasteride, and minoxidil.
In this conversation, 4990 discussed various treatments for hair loss, including oral minoxidil, PRP, transplan, Jak inhibitors, Dutasteride, Finasteride, Olumiant, Ketoconazole, RU58841, microneedling, baricitinib, and CCCA. They recommended scalp biopsies in unclear cases of DUPA, twice weekly to twice daily shampooing for topical minoxidil users, and two sessions spaced one month apart with follow up at month three to determine the effectiveness of PRP treatment.
Eli Lilly's drug baricitinib showed effectiveness in treating alopeciaareata, with higher doses resulting in significant hair regrowth compared to placebo. The treatment is not for male pattern baldness.
